Institution identification

PURI

https://redirect.ema.europa.eu/resource/1000000309

Institution ID

1000000309

Institution full name and acronym

Alfasigma

Institution countries

Italy

Type of institution

Pharmaceutical company

Institution role

Data holder

Institution website

ENCePP partner

No
Institution description
Alfasigma is one of Italy's leading pharmaceutical companies with a strong international positioning. The Group has a worldwide presence in over 100 countries where about 3000 people work in research, development, production and distribution. In Italy, Alfasigma is a leader in the prescription products market where, in addition to its strong focus on gastro-intestinal products, it is present in several primary care therapeutic areas. Its historical headquarters is in Bologna, to which is added Milan, while the production sites are: in Italy, in Pomezia (RM), Alanno (PE), Sermoneta (LT) and Trezzano Rosa (MI); and abroad in Tortosa (Spain) and in Shreveport (Louisiana, United States). The R&D laboratories are in Pomezia and in the Parco Scientifico Tecnologico Kilometro Rosso, Bergamo. Alfasigma's mission is to improve people's health and quality of life by offering caregivers and healthcare personnel therapeutic solutions according to the highest standards of quality and safety.
Institution details
Experience with collecting data directly from individual patients or respondents:
No
Interest in carrying out research that is funded by pharmaceutical companies:
No

Contact

Studies conducted by the institution

A prospective, non-interventional study in female patients with moderate to severe active rheumatoid arthritis in France receiving filgotinib for 2 years (PARROTFISH)
A prospective, non-interventional study of the effectiveness, safety, and health related outcomes in patients with moderate to severe active rheumatoid arthritis receiving filgotinib (FILOSOPHY)
A prospective, non-interventional, multi-country cohort study of the effectiveness and safety of filgotinib in adult patients with moderately to severely active ulcerative colitis (GALOCEAN)
Non-interventional post-authorization cohort safety study evaluating the effectiveness of the additional risk minimization measures for filgotinib (Jyseleca®) use in patients with moderate to severe active rheumatoid arthritis within European registries
Non-interventional post-authorization prospective cohort study evaluating the effectiveness of the additional risk minimization measures for filgotinib (Jyseleca®) use in patients with ulcerative colitis: a European multi registry-based study
Non-interventional post-authorization safety study of filgotinib in the treatment of patients with moderate to severe active rheumatoid arthritis within European registries
Non-interventional, post-authorization prospective safety study of filgotinib in patients with moderately to severely active ulcerative colitis: a European multi registry-based study